復宏漢霖-B(02696.HK)獲得商業化靶向人類BRAF蛋白V600E突變小分子抑制劑RX208在中國獨家權利
格隆匯3月28日丨復宏漢霖-B(02696.HK)公佈，公司於2021年3月27日與蘇州潤新生物科技有限公司訂立一份具約束力條款概要，據此，潤新生物同意授予公司在中國（含港澳台地區）開發、生產、商業化及再許可靶向人類BRAF蛋白V600E突變小分子抑制劑RX208的獨家權利。
公司應向潤新生物支付：於簽訂最終許可協議及完成許可產品的文件及技術轉移後，首付款合計人民幣9,750萬元；監管及商業銷售里程碑付款合計不超過人民幣10.775億元，基於許可產品的各項開發及商業銷售里程碑；及以年度淨銷售額的8%到12%計的特許權使用費，具體取決於許可地區內許可產品的年度淨銷售額水平。
據悉，許可產品RX208是靶向人類BRAF蛋白V600E突變的小分子抑制劑，在臨牀前研究中展現出優異的療效與安全性，目前處於1期臨牀開發階段。BRAF蛋白是MAPK/ERK信號通路中重要的上游調節因子，其V600E突變可使BRAF蛋白持續激活，是包括結直腸癌、甲狀腺瘤、黑色素瘤在內的多種腫瘤及脂質肉芽腫(ECD)等罕見病的潛在靶點。
潤新生物成立於2009年，註冊地位於江蘇省蘇州市，法定代表人為QIANXIANGPING。潤新生物由在生物醫藥領域擁有多年豐富經驗的歸國技術專家團隊創建，專注於抗腫瘤小分子創新藥物的研發，現有多個候選藥物在中國、美國、澳大利亞進行臨牀試驗。
公司表示，許可產品RX208是靶向BRAF蛋白V600E突變的小分子抑制劑，具有藥物活性強、選擇性高、毒副作用小的優點，未來有望開發成為更加安全、有效的BRAF V600E突變抑制劑，造福更多患者。本次合作可基於集團現有的藥物全產業鏈商業化平台，進一步豐富創新型產品管線，且許可產品或可能與本集團管線中的生物藥產生協同效應，進而增強本集團在腫瘤治療領域的綜合市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
